Direct binding of Copine3 with Jab1 activates downstream ErbB2 signaling and motility in SKBr3 breast cancer cells

HYE YOUNG CHOI1, NAMMI PARK2, JAE BOEM NA1, EUN SOOK KO3, JAE-YONG PARK4 and JAE CHEAL YOO5

1Department of Radiology, Gyeongsang National University Hospital, Jinju 660-702; 2Lab of Aquatic Animal Diseases, College of Veterinary Medicine, Gyeongsang National University, Jinju 660-701; 3Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710; 4School of Biosystem and Biomedical Science, College of Health Science, Korea University, Seoul 136-703, Republic of Korea

Received September 17, 2015; Accepted November 2, 2015

DOI: 10.3892/or.2015.4472

Abstract. Copine3 is a known calcium-dependent membrane binding protein, contains two tandem C2 domains and an A domain. This protein has been shown to interact with receptor tyrosine kinase 2 (ErbB2), but little is known concerning its physiological function of Copine3. To better understand its cellular function, we carried out a yeast two-hybrid screen to find Copine3 binding partners. Among the identified proteins, Jun activation domain-binding protein 1 (Jab1) appears to directly interact with Copine3. This physical interaction between Copine3 and Jab1 as well as the specific binding regions of both proteins were confirmed in vitro and in vivo. Our results also demonstrate that binding of Copine3 to ErbB2 is increased when Jab1 is overexpressed in SKBr3 breast cancer cells. Furthermore, two ErbB2 downstream signaling proteins [phosphatidylinositol 3 (PI3) kinase and protein kinase B (AKT)] were also activated by Jab1 overexpression in these cells. These data suggest that binding of Copine3 and Jab1 regulates, at least to some extent, the ErbB2 signaling pathway. Moreover, overexpression of both Copine3 and Jab1 in SKBr3 cells effectively increased cellular migration. Collectively, our findings indicating that Jab1 enhances the ErbB2 binding ability of Copine3, further activating the ErbB2 signaling pathways involved in breast cancer cell pathogenesis.

Introduction

Copines are a family of C2 domain-containing calcium-dependent lipid-binding proteins first identified in Paramecium tetraurelia and are evolutionally conserved from Arabidopsis to Homo sapiens (1). To date, nine human Copine family members have been identified (2,3). The various functions of this protein family have been shown to be related to cell growth, cancer development and neuronal differentiation (4-6). Copine3, a member of this family, is known to be a membrane binding protein with two tandem C2 domains, designated C2A and C2B, at the N-terminus followed by an ‘A domain’ in the C-terminal region (7). Previously, Copine3 was shown to bind to the phosphorylated Tyr1248 of receptor tyrosine kinase 2 (ErbB2), indicating that it may play a regulatory role in ErbB2-dependent breast cancer cell motility (8). However, the full mechanism of Copine3 in ErbB2 function is largely unknown.

Jun activation domain-binding protein 1 (Jab1) was originally cloned as a co-activator of activator protein 1 (AP-1) (9). Jab1, also named Cops5, is the fifth component of the COP9 signalosome complex (10), and is evolutionally conserved in mammals, plants and yeast (11). Furthermore, the deletion of Jab1 in mice results in early embryonic lethality due to impaired cellular proliferation and accelerated apoptosis (12,13). It has also been shown that Jab1 is involved in cell cycle progression, apoptosis, signal transduction and proliferation and is overexpressed in various types of cancer, including breast cancer (14-16).

In addition, several binding partners of Jab1 have been reported, further widening its function. For example, following interaction with Jab1, cyclin-dependent kinase inhibitor 1B (p27kip1) and tumor-suppressor p53 are degraded in the proteasome (17,18). In contrast, Jab1 appears to stabilize hypoxia-inducible factor 1α (HIF-1α) activation as well as the c-Jun/AP-1 complex (9,19). The binding of Jab1 to its various partners is likely mediated by one of its four binding domains, which include a Jun binding domain at the N-terminus followed by an Mpr1p and PAD1p N-terminal (MPN) domain. Other proteins with this MPN domain include proteasome regulatory subunits, eukaryotic initiation factor 3 (eIF3) subunits, and regulators of transcription factor expression and function (20). A nuclear export signal and p27 binding domain are also found in the C-terminal region of Jab1 (14). The presence of these various binding motifs likely mediates the binding of Jab1 to a number of its protein and protein complex partners (21).

In the present study, we have shown that Copine3 binds to Jab1 in vitro and in vivo, and have further investigated the
binding region between these two proteins. Furthermore, we also provide data supporting the ability of Jab1 to regulate Copine3-mediated ErbB2 signaling activity, whereby Jab1/Copine3 binding appears to increase ErbB2 protein activity as well as downstream cellular migration in SKBr3 breast cancer cells. To our knowledge, this is the first time Copine3/Jab1 binding and its downstream effects have been investigated.

Materials and methods

Plasmid constructs and mutagenesis. Full-length Copine3 cDNA (GenBank Accession No. NM_003909) was obtained using RT-PCR with RNA isolated from HEK 293T cells. The full-length clone was generated using this cDNA as a template via a PCR-based gateway cloning method previously described (22). C2A, C2B and A domain mutants were obtained using directed PCR in conjunction with primers specific for each region, thus deleting the other domains in the full-length cDNA transcript. Full-length Jab1 cDNA (GenBank Accession No. NM_006837) was obtained from the Korea Research Institute of Bioscience and Biotechnology (KRIBB; Daejeon, Korea; hMU009054). N-, MPN and C-terminal domains mutants were obtained using PCR primers specific for each domain. The resulting PCR products were cloned into the destination vector pDEST-AD-GFP using the gateway cloning system (Invitrogen).

Cell culture. The HEK 293T, COS7, SKBr3 and human breast cancer cell lines used in the present study were all maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% penicillin-streptomycin and 10% fetal bovine serum (FBS) at 37°C with 5% CO₂.

Yeast two-hybrid assay. The Copine3 gene was ligated into pGBK T7, which encodes a GAL4 DNA binding domain (BD), while the Jab1 gene was cloned into pGAD T7, which encodes an activation domain (AD). To assess the protein-protein interaction between Copine3 and Jab1, both BD/Copine3 and AD/Jab1 were co-transformed into the yeast strain AH109. The transformed yeast was then cultured in SD synthetic medium lacking leucine, tryptophan and histidine.

Adenovirus amplification and infection. Adenovirus was prepared and propagated in HEK 293A cells using the ViraPower™ Adenoviral Expression System (Invitrogen). pDEST-AD-GFP- and pDEST-AD-mcherry-tagged genes expression vectors were transfected into HEK 293A cells to obtain adenovirus particles. After 7-10 days, virus particles were harvested from the cells and media, followed by purification via centrifugation at 3,000 rpm for 15 min. For adenoviral infection, COS7 or SKBr3 cells were plated into 6-well plates at a density of 1x10⁵ cells/ml and infected with adenovirus at a multiplicity of infection (MOI) of 100. The infected cells were then incubated for 48 h at 37°C.

Confocal microscopy. For our imaging analysis, we used the COS7 cells infected with GFP-Copine3 and mcherry-Jab1 genes. Further, several randomly chosen fields from multiple wells of cells were photographed using a confocal microscope (Olympus FluoView FV1000).

Western blot analysis and immunoprecipitation (IP). HEK 293T and SKBr3 cells were lysed with RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM EDTA, 1 mM PMSF and 1% NP-40) containing a protease-inhibitor cocktail. Whole-cell lysates were incubated on ice for 30 min and then cleared at 20,000 x g for 20 min at 4°C. For the IP analysis, the resulting supernatants were incubated with the indicated antibodies for 3 h, at 4°C with an additional incubation for 2 h after the addition of protein A/G plus agarose (Santa Cruz Biotechnology). The immunocomplexes captured in the agarose gel were then washed three times with RIPA buffer and eluted by boiling with SDS gel-loading buffer. The immunoprecipitates were then analyzed by western blotting.

For the western blot analysis, the supernatants were separated by SDS-PAGE using 10% gels and blotted onto PVDF membranes. The blots were then probed with anti-Jab1 (1:1,000), anti-Copine3 (1:1,000) (both from Santa Cruz Biotechnology), anti-ErbB2 (1:2,000, Abcam), anti-PI3 kinase (1:1,000), anti-phospho-PI3 kinase (1:1,000) (both from Cell Signaling), anti-AKT1/2/3 (1:1,000), anti-phospho-AKT1/2/3 (S473; 1:1,000) and anti-GAPDH (1:3,000) (all from Santa Cruz Biotechnology) antibodies. Blots were then washed and incubated with horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit secondary antibodies, followed by additional washing and the detection with enhanced chemiluminescence (ECL; AbFrontier).

Wound-healing assay. SKBr3 cells (untreated, GFP-Copine3- and mcherry-Jab-infected) were inoculated into 6-well plates, and a 100 µl pipette tip was used to create a wound line across the cell monolayer. The cells that moved into the interspace of the scratched wound line were counted 48 h later using a phase contrast microscope. This assay was performed in triplicate.

Statistical analysis. Statistical analyses were performed with Origin8.0 software using an analysis of variance (ANOVA). Statistical significance was set at P<0.005. Data are reported as the means ± standard deviation (SD) of three independent experiments.

Results

Protein-protein interaction between Copine3 and Jab1 in vitro and in vivo. In order to identify novel Copine3 binding proteins, we performed a yeast two-hybrid screening using Copine3 as bait. One of the positive clones was determined to be Jab1 (data not shown). This protein-protein interaction between Copine3 and Jab1 was also confirmed using Jab1 as bait in a yeast two-hybrid assay (Fig. 1A) as well as an in vitro binding assay performed in 293T cells (Fig. 1B). These data clearly show that Copine3 binds directly to Jab1. Next, the interaction between these two proteins was further confirmed with confocal microscopy of Ad-mcherry-Jab1 and Ad-GFP-Copine3 infected COS7 cells. It appears that Jab1 localizes to the nucleus and cytosol region, particularly around the membrane, while Copine3 localizes to the around nucleus and cytosol (Fig. 1C). The areas where these two proteins are co-localized in the membrane are marked with an arrow (Fig. 1C).
We then evaluated the endogenous protein expression of ErbB2, Copine3 and Jab1 in several breast cancer cell types (Fig. 1D). To investigate the interaction between Jab1 and Copine3 and the effects of this interaction on ErbB2/Copine3-related pathways in breast cancer, endogenous co-IP experiments were carried out in SKBr3 cells. Notably, IP with anti-Jab1 and pre-serum antibodies, followed by western blotting with an anti-Copine3 antibody, showed that Jab1 is in fact associated with Copine3 in this cell type (Fig. 1E).

Identification of the binding regions involved in the Jab1/Copine3 interaction. To identify the specific binding regions involved for both proteins involved in the Jab1/Copine3 interaction, the N-terminus, MPN domain and C-terminus of Jab1 as well as the C2A, C2B, and A domains of Copine3 were isolated and N-terminally tagged with GFP (Fig. 2A and B for Jab1 and Copine3, respectively). These truncated mutants were then co-transfected into 293T cells with either FlAg-Copine3 (for the Jab1 mutants) or FlAg-Jab1 (for the Copine3 mutants). Our data indicate that, while Copine3 does not bind with the MPN domain of Jab1, it does interact with both the N- and C-terminal domains (Fig. 2A), indicating that the tertiary structure of Jab1 may be important during this binding interaction. Notably, Jab1 appears to bind only with the C2A domain of Copine3 (Fig. 2B), demonstrating that this region contains the binding site of Jab1. Generally, the C2 domains in Copine3 are known for their Ca ++ and lipid binding capabilities; however, our data indicate that at least the C2A domain also functions as a putative binding domain.

Jab1/Copine3 binding induces interaction between Copine3 and ErbB2, activating downstream ErbB2 signaling pathways in SKBr3 cells. It has been reported that Copine3 interacts with ErbB2 in various breast cancer cell types (8). To investigate the effect of Jab1 binding on the interaction between Copine3 and ErbB2, co-IP experiments were carried out in SKBr3 cells overexpressing Jab1 (Fig. 3A). It appears that the interaction between Copine3 and ErbB2 was markedly increased when Jab1 was overexpression in this cell type. In addition, to further confirm ErbB2 pathway activation, various downstream
signaling proteins were investigated. Notably, the levels of phosphorylated PI3 p85 kinase and AKT appear to increase when Jab1 is overexpressed in SKBr3 cells (Fig. 3B and C), indicating that high levels of Jab1, and thus an increase in...
Jab1/Copine3 binding, activate ErbB2-related signaling in this cell type. Based on these data, we conclude that Jab1 regulates ErbB2 downstream signaling pathway via binding to Copine3 and inducing the interaction between Copine3 and ErbB2.

**Discussion**

In the present study, we revealed a novel binding relationship between Copine3 and Jab1. This interaction was first demonstrated with a yeast two-hybrid screen using Copine3 as bait. Notably, we then confirmed this interaction in a reverse yeast two-hybrid screen with Jab1 as bait as well as using in vitro and in vivo assays. These assays further confirmed the co-localization of Copine3 and Jab1 and direct binding between the two proteins in breast cancer cells. The decision to focus on the role of these proteins specifically in breast cancer cells stemmed from a previous study that Copine3 expression correlates with ErbB2 amplification in breast cancer and preferentially binds to the pTyr1248 residue of this oncogene (8). This previous study also indicated that this Copine3/ErbB2 interaction occurs at the plasma membrane. Furthermore, Jab1 protein is also largely expressed in invasive breast cancer (23). Thus, the proximity of these proteins in breast cancer cells, confirmed in the present study, spurred us to investigate their possible influence on each other’s expression and function. Notably, in a preliminary analysis, we did not find any evidence supporting the direct binding of Jab1 with ErbB2 (data not shown), further focusing our investigation on the relationship between Jab1 and Copine3.

It is generally known that the A domain found in members of the Copine family is the primary protein binding domain involved in regulation, while the C2 domains are typically related to Ca++ and membrane binding (2). However, Benes et al revealed that the C2 domain of protein kinase Cδ (PKCδ) directly binds to phosphoryl-tyrosine peptides in a sequence-specific manner (24). In the present study, we have shown that the C2A domain of Copine3 is the only region involved in Jab1 binding. As this is one of the few studies identifying non-Ca++/membrane-dependent C2 domain-mediated binding, additional study is necessary to determine the full function of this binding motif.

Furthermore, Jab1 has been shown to bind to and degrade p27Kip1 and p53, while in other contexts it can stabilize HIF-1α activation and the c-Jun/AP-1 complex (9,17-19). The binding domains involved in these Jab1 functions are
found throughout the structure and include a Jun binding domain at the N-terminus, an MPN domain, as well as a p27 binding domain at the C-terminus (17-19). Generally, the function of the MPN domain has been related to ubiquitin isopeptidase/deubiquitinase in the ubiquitin-based signaling and protein turnover pathways in eukaryotes (20). Our data indicate that Copine3 preferentially binds with the N- and C-terminal regions of Jab1, thereby excluding the MPN domain. Notably, this distinct exclusion of MPN domain binding possibly indicates Jab1 binding-mediated activation of Copine3. In fact, our results show that binding of Jab1 and Copine3 activates Copine3/ErbB2 binding as well as the downstream ErbB2 signaling cascade and ErbB2-mediated cell migration. We believe that this Jab1/Copine3-mediated activation may involve Jab1 binding-induced conformation changes in the tertiary structure of Copine3, making this protein more accessible and/or more susceptible to ErbB2 binding. Additional studies identifying the specific binding sites and structural organization of the Jab1/Copine3 complex are warranted.

In conclusion, we have investigated the binding complex formed by Jab1 and Copine3 in breast cancer cells. Our data indicate that this binding complex not only forms in breast cancer cells, but also influences the ErbB2 binding capabilities of Copine3. It is likely that Copine3 is stabilized through the binding of Jab1, potentially allowing it to bind more strongly to ErbB2. Thus, Copine3 appears to be the link between Jab1 expression and ErbB2-mediated downstream signal pathways and cellular motility. The present study is the first to describe the Copine3/Jab1 interaction and further enhances our understanding of the signaling cascades involved in breast cancer.

Acknowledgements

The present study was supported by the Basic Science Research Program (NRF-2012R1A1A2005035) and the Bio-Synergy Research Project (NRF-2014M3A9C4066463) through the National Research Foundation of Korea.

References


